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Abstract
Tumors are inherently heterogeneous in antigen expres-
sion, and escape from immune surveillance due to antigen
loss remains one of the limitations of targeted immuno-
therapy. Despite the clinical use of adoptive therapy with
chimeric antigen receptor (CAR)–redirected T cells in lym-
phoblastic leukemia, treatment failure due to epitope
loss occurs. Targeting multiple tumor-associated antigens
(TAAs) may thus improve the outcome of CAR-T cell ther-
apies. CARs developed to simultaneously target multiple
targets are limited by the large size of each single-chain
variable fragment and compromised protein folding when
several single chains are linearly assembled. Here, we
describe single-domain antibody mimics that function with-
in CAR parameters but form a very compact structure. We
show that antibody mimics targeting EGFR and HER2 of the
ErbB receptor tyrosine kinase family can be assembled into
receptor molecules, which we call antibody mimic receptors
(amR). These amR can redirect T cells to recognize two
different epitopes of the same antigen or two different TAAs
in vitro and in vivo.
Introduction
Chimeric antigen receptors (CARs) are synthetic receptors. Their
specificity is determined by the single-chain variable fragment
(scFv) obtained from amonoclonal antibody, with their activation
controlled by the z-chain signaling domain from the T-cell receptor
complex and costimulatory endodomains (1, 2). Gene transfer of
CARs into T cells redirects T-cell antigen specificity through the
scFv. T-cell activation and proliferation is amplified through costi-
mulatory signals (3). The infusion of CAR-T cells in patients with
lymphoid malignancies has led to durable complete remission in
more than 40% of patients (4, 5). However, up to 20% of patients
with acute lymphoblastic leukemia receiving CD19-specific CAR-T
cells relapse due to the emergence of leukemic clones that have lost
the targeted epitope (4, 6). Furthermore, the heterogeneity of
tumor-associated antigen (TAA) expression in solid tumors leads
to CAR-T treatment failure when a single TAA is targeted (7).
The generation of multiredirected CAR-T cells, namely, by
recognition of two nonoverlapping epitopes of a TAA or two
different TAAs, may be necessary to effectively eradicate tumor
cells. Several approaches have been proposed to achieve this
goal including pooling CAR-T products targeting different TAAs,
generating vectors encoding two different CARs that can be
expressed simultaneously by each T cell, and engineering cas-
settes in which two scFvs are assembled into a single CAR
moiety (2, 8, 9). Although these approaches are feasible, a
challenge in using an scFv-based antigen receptor is the need
for multiple VH and VL domains to appropriately pair and
stabilize in complex structures. In addition to the complexity
and costs of manufacturing multiple T-cell products, reduced
expression of simultaneously expressed CARs, and compro-
mised protein folding when several scFvs are linearly assembled
in one single CAR, remain challenges to current methods of
generating multiredirected CAR-T cells.
Achieving multiple tumor-targeting features using scFv-based
CAR-T cells is difficult. We hypothesized that extracellular antigen
receptors with simple structure, high stability, and small size could
address the challenge. Various small protein domains that are not
structurally equivalent to the immunoglobulin domains have been
developed using various display technologies (10–14). Tumor-
homing ligands based on a small protein domain possess advan-
tages over those on a multidomain, complex structure in terms of
engineering higher modularity. Ideally, the scaffold should be a
monomeric smallproteindomainwithhigh solubility and stability
that is not inclined to aggregation, that tolerates sequence varia-
tions, and that is amenable to directed molecular evolution to
create antigen-binding ligands with multiple functions (13).
Among numerous scaffolds that have been examined, three
single-domain antibody mimics are of interest for developing
CARs with multiple tumor-targeting features: (i) monobody,
based on the type III domain of fibronectin (FN3); (ii) affibody,
based on a three-helix bundle Z domain; and (iii) DARPin, based
on the designed ankyrin repeat protein (11, 12, 15, 16). These
engineered proteins can have high specificity and affinity, despite
their simple structures and relatively small size. The FN3 domain
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broth (LB) plates containing 50 mg/mL kanamycin and 34 mg/mL
chloramphenicol. Single colonies were picked and grown over-
night at 37C. Overnight cell cultures were added to 1 L of LB
media and grown at 37C.When theOD600was between0.6 and
0.8, 1mmol/L IPTGwas added to induce expression for 4 hours at
37C. To purify the binding ligands, the cell pellet was resus-
pended in buffer A (25 mmol/L HEPES pH 7.4 and 300 mmol/L
NaCl) supplemented with 1 mmol/L phenylmethylsulfonyl fluo-
ride (PMSF) and sonicated on ice for 10minutes on a Sonifier 450
sonicator (Branson). After cell lysis, the soluble fraction was
recovered by centrifugation at 4C. The resulting soluble fraction
was loaded onto an IMAC Ni-charged affinity column (Bio-Rad)
preequilibrated with buffer A. The column was washed with
buffer A containing 20 mmol/L imidazole (buffer B) and then
50 mmol/L imidazole (buffer C) and the proteins were eluted
with buffer D (buffer A and 200 mmol/L imidazole). Following
dialysis against 1  PBS, the quality of the purified proteins was
verified by SDS-PAGE.
Characterization of target-binding features
Bio-layer interferometry (BLI) analyses of the monomeric and
heterodimeric EGFR andHER2-binding domainswere performed
on a Octet QK system (ForteBio LLC.) at 30 C. The ErbB binding
ligands and corresponding receptors diluted to required concen-
trations with an assay buffer (1 PBS, 1% BSA, 0.05% Tween 20,
pH 7.4) as well as the buffer are assigned to black 96 well plates
(Greiner Bio-One). Streptavidin (SA) biosensors (Fort_eBio)were
used to immobilize biotinylated ErbB binding ligands and ErbB
with Fc fusions(AcroBiosystems) at three different concentrations
ran against ligand binding SA sensors. Assays run in triplicatewere
acquired and analyzed on the ForteBio Data Acquisition 6.4
software. Savitzky–Golay filtering was applied to the averaged
reference biosensors and then globally fitted at a 1:1 model.
Cell lines
Tumor cell lines Panc-1, BxPC-3, HPAF-II, and AsPC-1 (pan-
creatic cancer), MCF-7 (breast cancer), and BV173 (B cell lym-
phoma) were purchased from ATCC. BxPC-3 and BV173 were
cultured in RPMI-1640 (Gibco). AsPC-1 was cultured in RPMI-
1640 supplemented with 1 mmol/L sodium pyruvate (Gibco).
HPAF-II and MCF-7 were cultured in MEM (Gibco). Panc-1 was
cultured in DMEM (Gibco). All media were supplemented with
10% FBS (Sigma), 2 mmol/L GlutaMax (Gibco) and penicillin
(100 units/mL) and streptomycin (100 mg/mL; Gibco). All cells
were maintained at 37C with 5% CO2. All cell lines are regularly
tested for Mycoplasma, and the identity of the cell lines was
validated by flow cytometry for relevant cell-surface markers and
were also monitored for morphological drift in culture. Cell lines
were maintained in culture no longer than 30 days and then
replaced with cells from stored vials. The number of previous
passages of these cell lines was unknown. Panc-1 cells were
transduced with a retroviral vector encoding the eGFP-Firefly-
Luciferase (eGFP-FFluc) gene (21). BV173 cells were transduced
with a retroviral construct encoding full-length human EGFR
to generate BV173-EGFR cells or a truncated form of HER2 to
generate BV173-HER2 cells. Panc-1 cells were transduced with a
retroviral vector encoding HER2 to make Panc-1-HER2.
Generation of redirected T cells
T cells expressing CAR and amRs were generated in
accordance with standard operating procedures currently used
is a stable protein with a molecular weight (MW) around 10 kDa. 
Structurally, it has a b-sandwich scaffold similar to that of the 
immunoglobulin VH domain, with putative ligand-binding sites 
composed of three solvent accessible surface loops that are struc-
turally analogous to the CDR H1, H2, and H3 of the VH 
domain (11). The advantage of the FN3 domain is in its lack of 
disulfide bonds and posttranslational modifications for biological 
functions. Affibodies (AFF) are based on the three-helix bundle Z 
domain derived from Staphylococcal protein A (17, 18). As with the 
FN3 domain, AFF domains are resistant to proteolysis and heat-
induced denaturation and lack disulfide bonds. Finally, DARPins 
contain consecutive copies of small structural repeats, which stack 
together to form a contiguous interacting surface (14). DARPin-
based targeting ligands that bind to various targets including CD4, 
EGFR, and HER2 have been generated (19).
Taking into consideration the simplicity, stability, and smaller 
size of these targeting ligands, as well as their current applications 
in therapeutics and diagnostics (20), we explored the use of these 
molecules in generating antigen-specific receptors for T cells. In 
particular, we investigated if a combination of these single-
domain antibody mimics allows the generation of a T-cell-surface 
antigen receptor that recognizes two different epitopes of the 
same tumor antigen or two different antigens, aiming to develop 
T cells with bispecific redirection targeting two epitopes of the 
same antigen or two different antigens. As proof of principle, we 
have adapted high-affinity antibody mimics specific for ErbB1 
(EGFR) and ErbB2 (HER2), to generate receptor molecules called 
antibody mimic receptors (amR).
Materials and Methods
Construction of bispecific CAR vectors
To construct bispecific CAR vectors, the codon-optimized (for 
expression in human cells) coding regions for a monomeric or 
heterodimeric EGFR- or/and HER2-binding ligand were fused 
through an optimized flexible linker. The final coding region was 
cloned into the SFG vector, resulting in a fusion protein that is 
composed of the signaling peptide from human IgG heavy-chain, 
EGFR- or HER2-binding domain(s), a FLAG tag, a 45-residue 
hinge region from the human CD8a extracellular domain, the 
transmembrane domain of human CD8a, the CD28-costimula-
tory endodomain, and the z chain of the TCR/CD3 complex (21). 
The CD8a hinge and transmembrane domains contain native 
cysteine residues. Single-domain antibody mimics (AFF, DARPin, 
and FN3) were PCR amplified and cloned into the SFG vector. The 
scFv derived from the cetuximab mAb was PCR amplified and 
cloned into the SFG vector. EGFR WT (Addgene plasmid 
#110110) and pBABE-puro-ErbB2 (Addgene plasmid #40978) 
were gifts from Matthew Meyerson Dana-Farber Cancer Institute. 
Full-length EGFR and HER2 were amplified by PCR and cloned 
into the SFG retroviral vector. A truncated form of HER2 lacking an 
intracellular domain was amplified by PCR and also cloned into the 
SFG retroviral vector. All retroviral supernatants were prepared as 
previously described (22).
Expression and purification of recombinant EGFR and HER2 
binding protein domains
Coding sequences codon-optimized for expression in E. coli 
with a C-terminal His tag were cloned into the pET28b vector. To 
express the ligands, vectors were transformed into E. coli BL21 
(DE3) Rosetta cells, and positive clones were selected on lysogeny
to manufacture CAR-T cells for clinical use at our institu-
tion (24, 25). Peripheral blood mononuclear cells were isolated
from discharged buffy coats (Gulf Coast Regional Blood Center)
using Lymphoprep medium (Accurate Chemical and Scientific
Corporation) and activated on plates coated with 1 mg/mL CD3
(Miltenyi Biotec) and CD28 (BD Biosciences) mAbs. Activated
T cells were transduced with retroviral supernatants on retro-
nectin-coated 24-well plates (Takara Bio Inc.) 2 to 3 days after
activation. Transduced T cells were expanded in 50% Click's
Medium (Irvine Scientific) and 50% RPMI-1640 supplemented
with 10% HyClone FBS (GE Healthcare), 2 mmol/L GlutaMax
(Gibco) and penicillin (100 units/mL) and streptomycin
(100 mg/mL; Gibco) with 10 ng/mL IL7 and 5 ng/mL of IL15
(PeproTech) for 10 to 14 days of culture before being used for
functional assays (24–26).
Flow cytometry
We used mAbs specific for human CD3 (APC-H7; SK7;
560176), CD45 (BV510; HI30; 563204), CD4 (BV711; SK3;
563028), CD8 (APC; SK1; 340584), CD19 (FITC; SJ25C1;
340409), CD45RA (PE; HI100; 555489), CD45RO (BV786;
UCHL1; 564290), CD69 (FITC; L78; 347823), and HER2 (PE;
Neu24.7; 340879) from BD Biosciences, CCR7 (FITC; 150503;
FAB197F-100) fromR&DSystems, and EGFR (PE; AY13; 352904)
from BioLegend. We detected the expression of the EGFR.CAR
or amRs using anti-FLAG mAb (APC; L5; 637308). An anti-
idiotype mAb was used to detect the expression of the CD19.
CAR as previously described (21). All samples were acquired
on a BD LSRFortessa, and a minimum of 10,000 events were
acquired per sample. Samples were analyzed on FlowJo 9
(FlowJo LLC).
Western blot analysis
T-cell lysateswere resuspended in 2 Laemelli buffer (Bio-Rad)
Proliferation assay
T cells were labeled with 1.5 mmol/L carboxyfluorescein dia-
cetate succinimidyl ester (CFSE; Invitrogen) and plated with
irradiated AsPC-1 at 4:1 effector-to-target (E:T) ratio in the
absence of exogenous cytokines. CFSE dilution of CAR-T cells or
amR-T cells was analyzed on day 5 using flow cytometry (21). The
proliferation index was quantified using FlowJo 9.
Long-term in vitro cytotoxicity
Tumor cells were seeded at 2.5–5  105 per well in 24-well
plates. Donor-matched T cells normalized for transduction effi-
ciency were added at 1:5 E:T ratio. On day 3–5 of coculture, cells
were collected, and the frequency of T cells and residual tumors
cells wasmeasured by flow cytometry. Tumor cells were identified
as CD19þ for BV173 tumor cells or CD4– CD8– in the case of all
adherent tumor cell lines (27).
Repetitive coculture assay
For multiple rounds of coculture, tumor cells were seeded at
5  105 per well in 24-well plates. Donor-matched T cells
normalized for transduction efficiency were added at 1:2 E:T
ratio. On day 3 of coculture, a fraction of the cells was
collected, and the frequency of T cells and residual tumors
cells was measured by flow cytometry. Between cocultures,
T cells were washed and resuspended in fresh medium, with-
out the addition of exogenous cytokines, and left to rest for 3
days (27).
Cytokine analysis
Supernatant was collected from 0.5–1  105 CAR-T cells or
amR-T cells plated in in vitro cytotoxicity assays at 1:5 E:T ratio after
24 hours or from 1.25 105 CAR-T cells or amR-T cells plated for
6 hours. IFNg and IL2 were measured by ELISA per the manu-
facturer's instructions (R&D Systems) in duplicate.
Xenograft murine models
Six- to 8-week-old male or female nonobese diabetic severe
combined immunodeficiency/gc/ (NSG) mice were injected
intravenously (i.v.) by tail vein with the Panc-1 tumor cell line
(1 106 cells/mouse) transducedwith theGFP-FFLuc reporter i.v.
by tail vein injection. In other experiments, HPAF-II GFP-FFLuc
tagged cells were suspended in Matrigel and inoculated intraper-
itoneally (i.p.; 1  106 cells/mouse). In rechallenge experiments,
Panc-1 GFP-FFLuc cells (1  106 cells/mouse) were injected
10 days prior to T-cell injection. Upon clearance of the Panc-1
tumor cells, mice were then infused with BV173-HER2 cells (2 
106 cells/mouse). Mice were matched based on the biolumines-
cence intensity and injected with 5 106 or 1 107 T cells i.v. 12
to 14 days after tumor cell engraftment. The IVIS-Kinetic Optical
System (PerkinElmer) was used to monitor tumor burden. Mice
were monitored and euthanized according to UNC-IACUC
Standards.
Statistical analysis
Data are reported as the mean and standard deviation, unless
otherwise reported. To compare significant differences between
two samples, a two-tailed Student t test was applied. An ANOVA
with Tukey post hoc analysis was applied when a comparison
betweenmultiple groups was required. A P value of less than 0.05
was considered statistically significant. All figures were generated
using GraphPad Prism (GraphPad Software).
in reducing or nonreducing conditions. To assess signaling 
through the CAR or amR, T cells on ice were incubated with 1 mg 
of anti-FLAG Ab (clone M2) for 15 minutes and then 1 mg of goat 
anti-mouse secondary Ab (BD Biosciences) for an additional 
15 minutes. Cells were then transferred to a 37C water bath 
for the indicated time points and lysed with 4 Laemelli buffer. 
All lysates were separated in 4% to 15% SDS-PAGE gels 
and transferred to polyvinylidene difluoride membranes (all 
Bio-Rad). Blots were probed for human CD3z (Santa Cruz Bio-
technology), p-Y142 CD3z (Abcam), pan-ERK (BD Biosciences), 
and pan-Akt, p-S473 Akt, and p-T202/Y204 MAPK (all Cell 
Signaling Technology) diluted 1:1,000 in TBS-Tween/5% skim 
milk. Membranes were then incubated with HRP-conjugated goat 
anti-mouse or goat anti-rabbit IgG (both Santa Cruz) at a dilution 
of 1:3,000 and imaged using the ECL Substrate Kit on a ChemiDoc 
MP System (both Bio-Rad) according to the manufacturer's 
instructions.
In vitro activation
Biotinylated recombinant EGFR and EGFRvIII protein (Acro-
Biosystems) were added to 96-well plates coated with 1 mg of  
avidin (Thermo Fisher Scientific) at a 3:1 ratio. Recombinant 
EGFR-Fc and HER2-Fc (R&D Systems) were coated on 96-well 
plates overnight at a concentration of 1 mg/well. T cells were 
seeded in duplicate or triplicate for 6 hours, and supernatant was 
collected for IFNg and T cells were assessed for CD69 by flow 
cytometry.
control nontransduced T cells (NTs), CD19.CAR-T cells, EGFR.
CAR-T cells, and Bi-EGFR.amR-T cells. NTs did not eliminate
either BV173-WT or BV173-EGFR cells, CD19.CAR-T cells elim-
inated both cell types (Supplementary Fig. S2B and S2C), and
Bi-EGFR.amR-T cells and EGFR.CAR-T cells only eliminated
BV173-EGFR cells (Supplementary Fig. S2B and S2C), indicating
the antigen specificity of the redirected T cells. Antitumor activity
was then tested against tumor cell lines that physiologically
express EGFR (Supplementary Fig. S2D). In coculture experi-
ments, Bi-EGFR.amR-T cells and EGFR.CAR-T cells demonstrated
similar antitumor activity in vitro (Fig. 2A) and released compa-
rable amounts of IFNg (Fig. 2B) and IL2 (Fig. 2C). Using a CFSE
dilution assay, we demonstrated the proliferation of Bi-EGFR.
amR-T cells in response to EGFR-expressing targets (Fig. 2D
and E). Finally, we evaluated the antitumor activity of Bi-EGFR.
amR-T cells in a metastatic model of EGFR-expressing pancreatic
cancer in NSG mice (Fig. 2F). Bi-EGFR.amR-T cells and EGFR.
CAR-T cells equally controlled human Panc-1 tumor cell growth
as assessed by measurement of tumor bioluminescence intensity
(Fig. 2G and H).
Bi-EGFR.amR-T cells recognize two nonoverlapping epitopes
of EGFR
AmRs composed of either the FN3.EGFR.amRor the AFF.EGFR.
amR alone were transduced in T cells (Supplementary Fig. S3A).
Both AFF.EGFR.amR-T cells and FN3.EGFR.amR-T cells showed
comparable activity in vitro against tumor cells expressing the full-
length EGFR (Supplementary Fig. S3B–S3F) and proliferated in
response to EGFR-expressing targets (Supplementary Fig. S3G and
S3H). To demonstrate the bispecific feature of the Bi-EGFR, we
analyzed the binding of Bi-EGFR and each of its monomeric
domains using the recombinant extracellular domain of the
wild-type EGFR (wtEGFR) and the EGFRvIII (EGFRvIII) mutant,
a constitutively active and ligand-independent variant of EGFR
with deletions in exons 2 to 7. We found that Bi-EGFR and Z
domain–based AFF.EGFR bound both wtEGFR and EGFRvIII.
However, FN3 domain–based FN3.EGFR bound to wtEGFR but
not EGFRvIII (Supplementary Fig. S4A), suggesting that it recog-
nizes an antigen encoded in the 267 AA that are absent in
EGFRvIII. To assess recognition of the two different EGFR epi-
topes, we used the extracellular domain of wtEGFR and EGFRvIII
mutant recombinant proteins. Control, AFF.EGFR.amR-T cells,
FN3.EGFR.amR-T cells, and Bi-EGFR.amR-T cells were seeded in
tissue culture plates coated with either wtEGFR or EGFRvIII, and
the CD69 expression and IFNg release by T cells were measured.
Both wtEGFR and EGFRvIII recombinant proteins activated AFF.
EGFR.amR-T cells and BiEGFR.amR-T cells, whereas only the
wtEGFR protein activated FN3.EGFR.amR-T cells (Fig. 3A–C),
indicating that the epitope recognized by the FN3.EGFR binding
moiety is either located in the 267 AA region deleted in EGFRvIII,
or the mutation has altered the epitope accessibility due to the
deletion-induced conformational changes. In contrast, the AFF.
EGFR binding moiety recognizes an epitope that is conserved
betweenEGFRandEGFRvIII (Fig. 3A–C). To ensure that bothAFF.
EGFR and FN3.EGFR binding moieties can induce the activation
of T cells when assembled into the Bi-EGFR.amR, we generated
an AFF.EGFR.amR mutant–binding moiety (mAFF.EGFR.amR)
in which critical residues at the EGFR-binding alpha helices
were mutated to alanine to reduce binding to EGFR. As shown
in Supplementary Fig. S4B, mAFF.EGFR.amR was expressed
in T cells, but mAFF.EGFR.amR-T cells did not eliminate
Results
A soluble single-domain antibody targets EGFR in a bispecific 
manner
To develop a single-domain–based tumor antigen–binding 
moiety that targets two different epitopes of EGFR, we assembled 
the previously identified Z domain–based EGFR-binding affibody 
ZEGFR:1907 and an FN3-based EGFR-binding monobody (17). 
The length and flexibility of the linker between the two EGFR-
binding domains were optimized to retain the target-binding 
affinity, specificity, and independent folding of each EGFR-
binding domain. We observed that when the linker is too short, 
both domains failed to bind targets. An overly long linker resulted 
in the loss of the bivalent effect as well as instability of the ligands. 
Because the linker length appeared to be antigen and binder 
dependent, we only used the linker length that worked well in 
this proof-of-concept work. In this study, the two antigen-binding 
moieties were separated by a 25-residue flexible linker. The 
resulting bispecific affinity molecule, from now on referred to 
as Bi-EGFR, binds to the extracellular domain of human EGFR 
at two nonoverlapping epitopes with an affinity (Kd) around 
0.38  0.07 nmol/L (Fig. 1A), which is approximately 10 times 
higher than that of the monomeric EGFR-binding FN3 domain 
(FN3.EGFR: 3.1  0.9 nmol/L; Fig. 1B) or Z domain (AFF.EGFR: 
3.2  0.3 nmol/L; Fig. 1C).
Bi-EGFR.amR T cells resemble those expressing conventional 
EGFR-specific CAR
To construct the CAR vector, the sequence of the biochemically 
optimized Bi-EGFR was fused to the CD28 and CD3z-chain sig-
naling domains via the CD8a hinge and transmembrane domains 
(21). To detect the expression of the Bi-EGFR.amR in T cells (Bi-
EGFR.amR-T cells) following transduction, we included a FLAG tag 
into the Bi-EGFR.amR cassette (Supplementary Fig. S1). A conven-
tional EGFR-specific CAR (EGFR.CAR) generated using the scFv 
derived from the monoclonal antibody cetuximab (Supplementary 
Fig. S1), and the CD19-specific CAR (CD19.CAR; ref. 21) were used 
as controls. AmRs composed of either the EGFR-A binding moiety 
(FN3.EGFR.amR) or the EGFR-B binding moiety (AFF.EGFR.amR) 
alone were also constructed (Supplementary Fig. S1). Upon retro-
viral gene transfer, T cells stably expressed the Bi-EGFR.amR 
(Fig. 1D and E), expanded in vitro in response to exogenous 
cytokines (Fig. 1F), and maintained T-cell composition comparable 
with EGFR.CAR-T cells and CD19.CAR-T cells (Fig. 1G). Western 
blot analysis of lysates from Bi-EGFR.amR-T cells detecting the 
CD3z chain under reducing conditions showed the native z-chain 
(17 kDa) and a band at the expected size of 55 kDa, indicating the 
integrity of the assembled Bi-EGFR.amR (Fig. 1H). We then ana-
lyzed proximal and distal signaling in EGFR.CAR-T cells and Bi-
EGFR.amR-T cells upon receptor cross-linking. As shown in Fig. 1I, 
receptor cross-linking in both Bi-EGFR.amR-T cells and EGFR.CAR-
T cells triggered similar phosphorylation of proximal (CD3z) and  
distal (Akt and ERK) signaling molecules.
Bi-EGFR.amR-T cells demonstrate activity against tumor cells 
expressing EGFR
To demonstrate that Bi-EGFR.amR-T cells specifically target 
EGFR, we used the EGFR– tumor cell line BV173 (BV173-WT) 
and transduced it to express EGFR (BV173-EGFR) with a retroviral 
vector encoding the full-length human EGFR (Supplementary Fig. 
S2A). We then cocultured BV173-WT or BV173-EGFR cells with
Figure 1.
Bi-EGFR.amR-T cells and conventional EGFR.CAR-T cells show comparable activity. A–C, Biolayer interferometry (BLI) was used to measure the affinity of the
monomeric or heterodimeric single-domain antibody mimics binding to recombinant Fc-EGFR on the ForteBio Octet system. Biotinylated antibody mimics
(100 nmol/L) were immobilized onto a streptavidin biosensor. Binding kinetics were measured against various concentrations of EGFR (0, 25, 50, and
100 nmol/L). The Kdwas calculated based on kinetic fitting. D, Representative expression of the Bi-EGFR.amR, EGFR.CAR, or CD19.CAR in T cells as assessed by
flow cytometry. Activated T cells were transduced with retroviral vectors encoding the Bi-EGFR.amR, EGFR.CAR, or CD19.CAR. With the exception of the CD19.
CAR, all constructs were detected using an anti-FLAG Ab. The CD19.CAR was detected using an anti-idiotype Ab. Shaded and unshaded histograms indicate
nontransduced and specific mAb, respectively. E, Summary of amR or CAR expression (n¼ 4). F, Expansion kinetics of Bi-EGFR.amR-T cells, EGFR.CAR-T cells,
or CD19.CAR-T cells NT (n¼ 4); error bars denote SD. G, Phenotypic composition of Bi-EGFR.amR-T cells, EGFR.CAR-T cells or CD19.CAR-T cells 10 days after
transduction (n¼ 4); error bars denote SD. H, Reducing immunoblots of Bi-EGFR.amR-T cell and EGFR.CAR-T cell lysates. Immunoblots were probed with
anti-CD3z. Top and bottom represent detection of the receptors and endogenous z-chain, respectively. I, EGFR.CAR-T cells and Bi-EGFR.amR-T cells were
incubated at the indicated time points with the anti-FLAG Ab and cross-linked with a secondary Ab to induce the aggregation of the receptors. Cell lysates were
immunoblotted to detect proximal (CD3z p-Y142) and distal (Akt p-S473 and ERK p-T202/204) phosphorylation events following receptor cross-linking. Total
CAR.CD3z or amR.CD3z and endogenous CD3zwere used as loading controls. Data are representative of 4 experiments.
BV173-EGFR cells (Supplementary Fig. S4C and S4D), indicating
that the mutations had abrogated binding to EGFR. However, T
cells expressing a Bi-EGFR.amR constructed with the FN3.EGFR
and mAFF.EGFR binding moieties (mBi-EGFR.amR) upregulated
CD69 and released IFNg when seeded in wells coated with
wtEGFR recombinant protein, but not in response to EGFRvIII
protein, indicating that the FN3.EGFR binding moiety alone can
induce T-cell activation when the function of the other EGFR-
binding moiety (AFF.EGFR) is abolished in the mBi-EGFR.amR
(Fig. 3D–F).
Bispecific amR against HER2 demonstrates antitumor activity
We also constructed an amR receptor against another member
of the ErbB family of receptor tyrosine kinase, HER2, to demon-
strate the applicability of this technology to other TAAs. Using a
similar approach to the construction of Bi-EGFR, a tumor
antigen–binding moiety that targets two different epitopes of
HER2 (Bi-HER2) was generated, which showed a HER2-
binding affinity (Kd) around 0.25  0.04 nmol/L (Fig. 4A),
compared with 1.8  0.6 nmol/L (Fig. 4B) of a HER2-binding
DARPin (15) and 1.3 0.4 nmol/L of a HER2-binding Z domain
Figure 2.
Bi-EGFR.amR-T cells show activity against EGFR-expressing tumor cells in vitro and in vivo.A, Control T cells (NTs or CD19.CAR-T cells), Bi-EGFR.amR-T cells,
and EGFR.CAR-T cells were cocultured with MCF-7 cells (EGFR negative) or EGFR-expressing pancreatic adenocarcinoma cell lines (AsPC-1, BxPC-3, HPAF-II,
and Panc-1) at 1:5 E:T ratio. Cells were collected and quantified by flow cytometry on day 5. The frequency of residual tumor cells was identified as CD4CD8 live
cells (n¼ 3–4), P < 0.01 when Bi-EGFR.amR-T cells or EGFR.CAR-T cells are compared with control T cells; two-way ANOVAwith Tukey correction. B, IFNg and
(C) IL2 released in the coculture supernatant by Bi-EGFR.amR-T cells, EGFR.CAR-T cells, and control T cells after 24 hours of coculture with tumor cells as
assessed by ELISA (n¼ 3–4), P < 0.01 when Bi-EGFR.amR-T cells or EGFR.CAR-T cells are compared with control T cells; two-way ANOVAwith Tukey correction.
D, Bi-EGFR.amR-T cells, EGFR.CAR-T cells or control T cells were labeled with CFSE and stimulated with irradiated EGFR-expressing AsPC-1 cells at 4:1 E:T.
Representative CFSE dilution on day 5. E, Proliferation index as assessed by CFSE dilution (n¼ 4), P < 0.01 when Bi-EGFR.amR-T cells or EGFR.CAR-T cells are
compared with control T cells; one-way ANOVAwith Tukey correction. F, Schematic representation of a metastatic pancreatic cancer model in NSGmice using
the FFLuc-labeled human Panc-1 cell line. Representative images of tumor bioluminescence (BLI) (G) and kinetics (H) of tumor growth as assessed by BLI
measurements. Data are representative of two independent experiments with 5 mice per group; P < 0.01 when Bi-EGFR.amR-T cells or EGFR.CAR-T cells are
compared with control T cells; two-way ANOVAwith Tukey correction.
metastatic tumor model of HER2-expressing human HPAF-II
pancreatic cancer in NSG mice (Fig. 4G). Bi-HER2.amR-T cells
and EGFR.CAR-T cells equally controlled tumor cell growth as
assessed by measurement of tumor bioluminescence intensity
(Fig. 4H and I).
Bispecific EGFR-HER2.amR-T cells target tumor cells expressing
EGFR and HER2
To generate amRs targeting two different TAAs, we integrated
the EGFR-specific FN3 binding moiety and the HER2-specific
DARPin binding moiety and created the EGFR-HER2.amR with
a 27-residue flexible linker between the two antigen-binding
moieties (Supplementary Fig. S6A). T cells stably expressed the
Figure 3.
Bi-EGFR.amR-T cells are activated by recognition of two nonoverlapping epitopes on EGFR. Control (NTs), AFF.EGFR.amR-T cells, FN3.EGFR.amR-T cells, and
Bi-EGFR.amR-T cells were seeded in tissue culture plates coated with either recombinant human EGFRWT protein (EGFR) or the truncated mutant EGFRvIII
recombinant protein (EGFRvIII).A, Representative expression of CD69 on NTs, AFF.EGFR.amR-T cells, FN3.EGFR.amR-T cells, and Bi-EGFR.amR-T cells 6 hours
after stimulation with plate-bound EGFR or EGFRvIII protein as assessed by flow cytometry. Shaded and dashed histograms indicate media and PMA/Iono
controls, respectively. Solid and dashed lines indicate EGFR and EGFRvIII protein stimulation, respectively. B, Summary of CD69 expression on total live T cells (n
¼ 4), P < 0.01 when comparing FN3.EGFR.amR-T cells seeded in EGFR and EGFRvIII-coated wells; two-way ANOVAwith Tukey correction. C, IFNg released in the
supernatant by AFF.EGFR.amR-T cells, FN3.EGFR.amR-T cells, and Bi-EGFR.amR-T cells as assessed by ELISA (n¼ 3), P < 0.01 when comparing FN3.EGFR.amR-
T cells seeded in rEGFR and rEGFRvIII-coated wells; two-way ANOVAwith Tukey correction. D,mAFF.EGFR.amR-T cells or mBi-EGFR.amR-T cells were
cocultured with BV173-WT or BV173-EGFR cells at 1:5 E:T for 3 days. CD19.CAR-T cells were used as a positive control. Cells were collected, and T cells (CD3þ)
and tumor cells (CD19þ) were quantified by flow cytometry. Representative flow plots are illustrated. E,Quantification of BV173-WT or BV173-EGFR cells
remaining after 3 days of coculture. F, IFNg released in the supernatant by NT, CD19.CAR-T, mAFF.EGFR.amR-T, and mBi-EGFR.amR-T cells as assessed by ELISA
(n¼ 2–4), P < 0.01 when comparing the percentage of residual BV173-WT and BV173-EGFR cells remaining in the mBi-EGFR.amR-T wells; two-way ANOVAwith
Tukey correction.
(ref. 18; Fig. 4C), respectively. Based on this HER2-binding ligand, 
a bispecific Bi-HER2.amR was constructed (Supplementary Fig. 
S5A). T cells stably expressed the Bi-HER2.amR (Bi-HER2.amR-T 
cells) upon retroviral transfer, expanded in vitro in response to 
exogenous cytokines (Supplementary Fig. S5B) and maintained 
T-cell composition comparable to control T cells (Supplementary 
Fig. S5C). Bi-HER2.amR-T cells demonstrated targeting of HER2-
expressing cells (Supplementary Fig. S5D–S5F). Furthermore, 
Bi-HER2.amR-T cells exhibited antitumor activity (Fig. 4D) and 
released IFNg (Fig. 4E) and IL2 (Fig. 4F) in a HER2-dependent 
manner when cocultured with tumor cell lines expressing HER2, 
but not with HER2-negative cell lines (Supplementary Fig. S5D). 
We also evaluated the efficacy of Bi-HER2.amR-T cells in a
EGFR-HER2.amR (Supplementary Fig. S6B and S6C), expanded
in vitro in response to exogenous cytokines (Supplementary
Fig. S6D) and maintained T-cell composition comparable to
monospecific FN3.EGFR.amR-T cells and DARPin.HER2.amR-T
cells (Supplementary Fig. S6E). To establish the bispecificity of
EGFR-HER2.amR-T cells, we seeded control, FN3.EGFR.amR-T
cells, DARPin.HER2.amR-T cells, and EGFR-HER2.amR-T cells in
tissue cultures plates coated with either the extracellular domain
of rhEGFR or rhHER2 recombinant proteins and assessed CD69
expression and IFNg release by T cells. EGFR-HER2.amR-T cells
expressed CD69 (Supplementary Fig. S6F) and secreted IFNg
(Supplementary Fig. S6G) when seeded in wells coated with
either rhEGFR or rhHER2 proteins, whereas FN3.EGFR.amR-T
cells and DARPin.HER2.amR-T cells were only activated by
Figure 4.
Bi-HER2.amR-T cells have antitumor activity against HER2-expressing primary cells in vitro and in vivo. A–C, Biolayer interferometry (BLI) was used to measure
the affinity of the monomeric or heterodimeric single-domain antibody mimics binding to recombinant Fc-HER2 using the ForteBio Octet system. Biotinylated
antibody mimics (100 nmol/L) were immobilized onto a streptavidin biosensor. Binding kinetics was measured against various concentrations of HER2 (0, 25, 50,
100 nmol/L). The Kdwas calculated based on kinetic fitting. D, Control T (NT), Bi-HER2.amR-T cells, and EGFR.CAR-T cells were cocultured with Panc-1 cells (HER
negative) or HER2-expressing pancreatic adenocarcinoma cell lines (AsPC-1 and HPAF-II) at 1:5 E:T. Cells were collected and quantified by flow cytometry on day
5. The frequency of residual tumor cells was identified as CD4 CD8 live cells (n¼ 3–6), P < 0.01 when comparing Bi-HER2.amR-T cells or EGFR.CAR-T cells with
NTs; two-way ANOVAwith Tukey correction. E, IFNg and (F) IL2 released in the coculture supernatant by NTs, Bi-HER2.amR-T cells or EGFR.CAR-T cells after 24
hours of coculture with tumor cells as assessed by ELISA (n¼ 3–6), P < 0.01 when comparing Bi-HER2.amR-T cells or EGFR.CAR-T cells with NTs; two-way
ANOVAwith Tukey correction. G, Schematic representation of a metastatic pancreatic cancer model in NSGmice using the FFLuc-labeled human HPAF-II cell
line. Representative images of tumor bioluminescence (BLI) (H) and kinetics (I) of tumor growth as assessed by BLI measurements. Data are representative of
two independent experiments with 5 mice per group; P < 0.01 when Bi-HER2.amR-T cells or EGFR.CAR-T cells are compared with NTs; two-way ANOVAwith
Tukey correction.
Figure 5.
EGFR-HER2.amR-T cells show dual specificity. Coculture experiment in which T cells were plated with its respective BV173 target cells, and 3 days later T cells
were collected and replated with the same BV173 tumor cell line or BV173 cells expressing the nonspecific target. A, Schema of the repetitive coculture
experiments with control (CD19.CAR-T cells), monospecific FN3.EGFR.amR-T cells, DARPin.HER2.amR-T cells, and bispecific EGFR-HER2.amR-T cells all plated at
1:2 E:T ratio. B, Representative flow plots of the repetitive coculture experiments on the second round. Cells were collected and quantified by flow cytometry on
day 3. The frequency of residual tumor cells was identified as CD3CD19þ live cells. C,Quantification of tumor cells remaining after the second coculture (n¼ 2–
3), P < 0.01 when comparing FN3.EGFR.amR-T cells and DARPin.HER2.amR-T cells and their respective targets againstWT tumor cells; two-way ANOVAwith
Tukey correction. D, IFNg released in the coculture supernatant by CD19.CAR-T cells, FN3.EGFR.amR-T cells, DARPin.HER2-amR-T cells, or EGFR-HER2.CAR-T
cells after 24 hours of coculture with tumor cells as assessed by ELISA (n¼ 2–3), P < 0.01 when comparing FN3.EGFR.amR-T cells and DARPin.HER2.amR-T cells
and their respective targets against WT cells; two-way ANOVAwith Tukey correction. E, Schematic representation of the rechallenge tumor model in NSGmice
using the EGFRþHER2 human Panc-1 cell line labeled with the FF-Luc and the EGFRHER2 human BV173-HER2 cell line. Representative images of the Pan-1
tumor BLI (F) and BLI kinetics (G) of tumor growth of one experiment 3–7mice per group. H, Kaplan–Meier survival curve of NSGmice after rechallenge with the
BV173-HER2 cell line; P < 0.01 when mice treated with EGFR.amR-T cells are compared with mice treated with EGFR-HER2.amR-T cells.
alternative mRNA splicing, which may cause loss of a targeted
epitope (6). When the AFF.EGFR and FN3.EGFR were combined
in one single amR cassette, we demonstrated that two epitopes of
EGFR can be targeted without causing detrimental effects in T
cells. Targeting two distinct antigens expressed by tumor cells
remains challenging. We demonstrated that single-domain anti-
bodymimics can be assembled in one single cassette to efficiently
target two different antigens. As a proof of principle, we showed
that both EGFR and HER2 can be effectively targeted by dual-
specific amRs neither with impairing targeting of each single
antigen nor with detrimental effects of engineered T cells.
In summary, we provided proof of concept that antibody
mimics can be used to generate combinatorial targeting of engi-
neered T cells. Taking in consideration that antibody mimics are
generated synthetically, our proposed approach can be adapted to
a systematic screening of combinatorial antigens to be tested in
human malignancies.
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